Evolus (EOLS) Non-Current Assets (2017 - 2026)
Evolus (EOLS) posted Non-Current Assets of $81.7 million for Q1 2026, down 1.48% on a QoQ basis from $83.0 million in Q4 2025, and little changed year-over-year from $81.6 million in Q1 2025.
Evolus (EOLS) Non-Current Assets (2017 - 2026) Analysis & Trends
Evolus' Non-Current Assets history runs 10 years deep, the most recent figure standing at $81.7 million for Q1 2026.
- Quarterly Non-Current Assets changed 0.1% year-over-year to $81.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $332.6 million (up 4.68% YoY) and the FY2025 annual result came in at $83.0 million, up 2.12% from the prior year.
- Non-Current Assets was $81.7 million for Q1 2026 at Evolus, down from $83.0 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $84.1 million in Q3 2025 and bottomed at $72.5 million in Q2 2023.
- A 5-year average of $78.6 million and a median of $77.2 million in 2022 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets retreated 5.78% — and 2025, when it gained 10.83%.
- Evolus' Non-Current Assets stood at $77.2 million in 2022, then fell by 0.78% to $76.6 million in 2023, then rose by 6.07% to $81.2 million in 2024, then rose by 2.12% to $83.0 million in 2025, then fell by 1.48% to $81.7 million in 2026.
- Business Quant data shows EOLS's Non-Current Assets at $81.7 million in Q1 2026, $83.0 million in Q4 2025, and $84.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Evolus | 390.47 Mn | 340.68 Mn | 48.90 Mn | 81.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 81.72 Mn |
| Dec 31, 2025 | 82.95 Mn |
| Sep 30, 2025 | 84.11 Mn |
| Jun 30, 2025 | 83.83 Mn |
| Mar 31, 2025 | 81.64 Mn |
| Dec 31, 2024 | 81.23 Mn |
| Sep 30, 2024 | 79.25 Mn |
| Jun 30, 2024 | 75.64 Mn |
| Mar 31, 2024 | 75.91 Mn |
| Dec 31, 2023 | 76.58 Mn |
| Sep 30, 2023 | 75.97 Mn |
| Jun 30, 2023 | 72.52 Mn |
| Mar 31, 2023 | 76.15 Mn |
| Dec 31, 2022 | 77.18 Mn |
| Sep 30, 2022 | 76.77 Mn |
| Jun 30, 2022 | 76.97 Mn |
| Mar 31, 2022 | 77.73 Mn |
| Dec 31, 2021 | 78.68 Mn |
| Sep 30, 2021 | 76.88 Mn |
| Jun 30, 2021 | 77.97 Mn |